Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for AlopeciaGlobeNewsWire • 12/05/23
Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 12/04/23
Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)Zacks Investment Research • 11/16/23
Aclaris Therapeutics pulls arthritis drug research program; shares plummetProactive Investors • 11/13/23
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate UpdateGlobeNewsWire • 11/13/23
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 11/06/23
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)GlobeNewsWire • 10/03/23
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/20/23
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 InhibitorGlobeNewsWire • 09/18/23
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 08/07/23
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)GlobeNewsWire • 06/13/23
Aclaris Therapeutics to Participate in Two June Healthcare Investor ConferencesGlobeNewsWire • 06/02/23
Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 05/08/23
Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023GlobeNewsWire • 05/02/23
Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual ConferenceGlobeNewsWire • 03/27/23